CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,134 enrolled
Drug / intervention
cyclophosphamide +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00433459
NCT00433459Phase 3Completed
CompareCT.gov

First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents

Christine Mauz-Körholz·interventional·Posted Feb 12, 2007·Updated Mar 26, 2020

In Brief

A Phase 3 clinical trial evaluating cyclophosphamide, dacarbazine, and 6 other interventions for Lymphoma. Completed, enrolled 2,134 participants across 2 sites in 2 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesGermany, United Kingdom
CollaboratorsDeutsche Krebshilfe e.V., Bonn (Germany), Euronet Worldwide

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 12, 2007
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 19.4 years ago

Interventions

cyclophosphamidedrug

drug is used in first line treatment in combination (COPP or COPDAC)

dacarbazinedrug

drug is used in first line treatment in combination (COPDAC)

prednisolonedrug

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

prednisonedrug

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

procarbazine hydrochloridedrug

drug is used in first line treatment in combination (COPP)

vincristine sulfatedrug

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

fludeoxyglucose F 18radiation

used as a diagnostic marker for metabolically active tumour at staging and response assessment

radiation therapyradiation

part of combination treatment (combined modality between chemo- and radiotherapy)